{"id":937041,"date":"2026-02-13T16:25:48","date_gmt":"2026-02-13T21:25:48","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/philadelphia-jury-returns-250000-verdict-against-jj-in-latest-baby-powder-ovarian-cancer-trial\/"},"modified":"2026-02-13T16:25:48","modified_gmt":"2026-02-13T21:25:48","slug":"philadelphia-jury-returns-250000-verdict-against-jj-in-latest-baby-powder-ovarian-cancer-trial","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/philadelphia-jury-returns-250000-verdict-against-jj-in-latest-baby-powder-ovarian-cancer-trial\/","title":{"rendered":"Philadelphia Jury Returns $250,000 Verdict Against J&J in Latest Baby Powder-Ovarian Cancer Trial"},"content":{"rendered":"

<\/p>\n

Philadelphia Jury Returns $250,000 Verdict Against J&J in Latest Baby Powder-Ovarian Cancer Trial<\/b><\/p>\n

Outcome marks the first of several trials scheduled for 2026<\/i><\/p>\n

PHILADELPHIA–(BUSINESS WIRE<\/a>)–
\nA jury in the Philadelphia Court of Common Pleas has found Johnson & Johnson (NYSE:JNJ<\/a>) responsible for the company\u2019s baby powder products contributing to the death of a Pennsylvania woman.<\/p>\n

\nThe jury deliberated for more than three days before returning a verdict totaling $250,000 on behalf of the estate of York, Pennsylvania, resident Gayle Emerson, who died as a result of ovarian cancer in November of 2019 after filing her lawsuit six months earlier. The verdict included $50,000 in compensatory damages to Ms. Emerson\u2019s family and $200,000 in punitive damages against the company on claims of product liability, failure to warn about the products\u2019 dangers, and negligence.<\/p>\n

\nAccording to court testimony, Ms. Emerson used J&J\u2019s talc-based body powders for feminine hygiene for more than 45 years and was diagnosed with ovarian cancer in 2015 at the age of 64.<\/p>\n

\n\u201cIt\u2019s important to note that this jury found J&J\u2019s product and corporate conduct directly responsible for the death of Ms. Emerson. While the jury\u2019s award is less than we hoped, and significantly less than the amount necessary to punish J&J for their outrageous conduct, we are moving forward. Our legal system is once again able to resume holding this giant company accountable for the death and devastation it has caused,\u201d says Leigh O\u2019Dell of the Beasley Allen Law Firm, who tried the case with David Dearing of Beasley Allen and Richard Golomb of Golomb Legal. \u201cThe evidence is clear that the company knew that its talc-based products were routinely contaminated with asbestos and other carcinogens but chose to deny and cover up that knowledge for decades. In addition, we will also review the trial record and consider appropriate avenues for post-trial motions.\u201d<\/p>\n

\nThe trial was the first of several scheduled to be tried in 2026 in courts across the nation on similar claims, including more than 70,000 lawsuits currently consolidated in multidistrict litigation in New Jersey federal court. The initial bellwether trial in that MDL is expected to be tried later this year.<\/p>\n

\nJohnson & Johnson made three unsuccessful attempts to consolidate talc liability claims under bankruptcy protection beginning in 2021, which created a pause on all litigation until last year. In 2020, J&J announced the company would no longer make or market talc-based powders for the North American market, a ban that was expanded in 2023 to include all worldwide sales.<\/p>\n

\nIn December a Los Angeles County jury ordered Johnson & Johnson to pay a combined $40 million to two women on ovarian cancer claims, the first such trial following the company\u2019s more than three years of bankruptcy-related delays. In addition, in the fourth quarter of 2025 the company suffered more than $2 billion in combined trial losses based on claims that talc exposure resulted in mesothelioma.<\/p>\n

\nIn January, J&J reported 2025 revenues of $94.2 billion while anticipating more than $100 billion in annual revenue by year-end 2026.<\/p>\n

\nMore than 30 peer-reviewed medical studies published in the last 40 years have found a statistically significant correlation between talcum powder use and ovarian cancer. Most recently, scientists from the International Agency for Research on Cancer (IARC) raised the organization\u2019s classification of the cancer risk stemming from genital talc use to \u201cprobable,\u201d while a May 2024 study published by National Institutes of Health researchers in the Journal of Clinical Oncology<\/i> found a \u201csignificant increase\u201d in the data that supports \u201cthe plausibility of a true association between genital powder use and ovarian cancer risk.\u201d<\/p>\n

\nFurther research has demonstrated that talc particles, when applied to the perineal area, can migrate to the ovaries and result in inflammation and related malignancies.<\/p>\n

\nThe case is Emerson v. Johnson & Johnson<\/i>, No.190509334, in the Court of Common Pleas of Philadelphia County, Pennsylvania.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260213785015\/en\/<\/a><\/span><\/p>\n

Media Contact:
\n
<\/b>Barry Pound
\n
214-559-4630
\n
barry@androvett.com<\/a><\/p>\n

KEYWORDS:<\/b> United States North America Pennsylvania<\/p>\n

INDUSTRY KEYWORDS:<\/b> Professional Services Oncology Health Consumer Legal Women<\/p>\n

MEDIA:<\/b><\/p>\n\n","protected":false},"excerpt":{"rendered":"

Philadelphia Jury Returns $250,000 Verdict Against J&J in Latest Baby Powder-Ovarian Cancer Trial Outcome marks the first of several trials scheduled for 2026 PHILADELPHIA–(BUSINESS WIRE)– A jury in the Philadelphia Court of Common Pleas has found Johnson & Johnson (NYSE:JNJ) responsible for the company\u2019s baby powder products contributing to the death of a Pennsylvania woman. The jury deliberated for more than three days before returning a verdict totaling $250,000 on behalf of the estate of York, Pennsylvania, resident Gayle Emerson, who died as a result of ovarian cancer in November of 2019 after filing her lawsuit six months earlier. The verdict included $50,000 in compensatory damages to Ms. Emerson\u2019s family and $200,000 in punitive damages against the company on claims … <\/p>\n

Continue reading “Philadelphia Jury Returns $250,000 Verdict Against J&J in Latest Baby Powder-Ovarian Cancer Trial”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-937041","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nPhiladelphia Jury Returns $250,000 Verdict Against J&J in Latest Baby Powder-Ovarian Cancer Trial - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/philadelphia-jury-returns-250000-verdict-against-jj-in-latest-baby-powder-ovarian-cancer-trial\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Philadelphia Jury Returns $250,000 Verdict Against J&J in Latest Baby Powder-Ovarian Cancer Trial - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Philadelphia Jury Returns $250,000 Verdict Against J&J in Latest Baby Powder-Ovarian Cancer Trial Outcome marks the first of several trials scheduled for 2026 PHILADELPHIA–(BUSINESS WIRE)– A jury in the Philadelphia Court of Common Pleas has found Johnson & Johnson (NYSE:JNJ) responsible for the company\u2019s baby powder products contributing to the death of a Pennsylvania woman. The jury deliberated for more than three days before returning a verdict totaling $250,000 on behalf of the estate of York, Pennsylvania, resident Gayle Emerson, who died as a result of ovarian cancer in November of 2019 after filing her lawsuit six months earlier. The verdict included $50,000 in compensatory damages to Ms. Emerson\u2019s family and $200,000 in punitive damages against the company on claims … Continue reading "Philadelphia Jury Returns $250,000 Verdict Against J&J in Latest Baby Powder-Ovarian Cancer Trial"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/philadelphia-jury-returns-250000-verdict-against-jj-in-latest-baby-powder-ovarian-cancer-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-13T21:25:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260213785015r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/philadelphia-jury-returns-250000-verdict-against-jj-in-latest-baby-powder-ovarian-cancer-trial\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/philadelphia-jury-returns-250000-verdict-against-jj-in-latest-baby-powder-ovarian-cancer-trial\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Philadelphia Jury Returns $250,000 Verdict Against J&J in Latest Baby Powder-Ovarian Cancer Trial\",\"datePublished\":\"2026-02-13T21:25:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/philadelphia-jury-returns-250000-verdict-against-jj-in-latest-baby-powder-ovarian-cancer-trial\\\/\"},\"wordCount\":692,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/philadelphia-jury-returns-250000-verdict-against-jj-in-latest-baby-powder-ovarian-cancer-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260213785015r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/philadelphia-jury-returns-250000-verdict-against-jj-in-latest-baby-powder-ovarian-cancer-trial\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/philadelphia-jury-returns-250000-verdict-against-jj-in-latest-baby-powder-ovarian-cancer-trial\\\/\",\"name\":\"Philadelphia Jury Returns $250,000 Verdict Against J&J in Latest Baby Powder-Ovarian Cancer Trial - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/philadelphia-jury-returns-250000-verdict-against-jj-in-latest-baby-powder-ovarian-cancer-trial\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/philadelphia-jury-returns-250000-verdict-against-jj-in-latest-baby-powder-ovarian-cancer-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260213785015r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2026-02-13T21:25:48+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/philadelphia-jury-returns-250000-verdict-against-jj-in-latest-baby-powder-ovarian-cancer-trial\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/philadelphia-jury-returns-250000-verdict-against-jj-in-latest-baby-powder-ovarian-cancer-trial\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/philadelphia-jury-returns-250000-verdict-against-jj-in-latest-baby-powder-ovarian-cancer-trial\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260213785015r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260213785015r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/philadelphia-jury-returns-250000-verdict-against-jj-in-latest-baby-powder-ovarian-cancer-trial\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Philadelphia Jury Returns $250,000 Verdict Against J&J in Latest Baby Powder-Ovarian Cancer Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Philadelphia Jury Returns $250,000 Verdict Against J&J in Latest Baby Powder-Ovarian Cancer Trial - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/philadelphia-jury-returns-250000-verdict-against-jj-in-latest-baby-powder-ovarian-cancer-trial\/","og_locale":"en_US","og_type":"article","og_title":"Philadelphia Jury Returns $250,000 Verdict Against J&J in Latest Baby Powder-Ovarian Cancer Trial - Market Newsdesk","og_description":"Philadelphia Jury Returns $250,000 Verdict Against J&J in Latest Baby Powder-Ovarian Cancer Trial Outcome marks the first of several trials scheduled for 2026 PHILADELPHIA–(BUSINESS WIRE)– A jury in the Philadelphia Court of Common Pleas has found Johnson & Johnson (NYSE:JNJ) responsible for the company\u2019s baby powder products contributing to the death of a Pennsylvania woman. The jury deliberated for more than three days before returning a verdict totaling $250,000 on behalf of the estate of York, Pennsylvania, resident Gayle Emerson, who died as a result of ovarian cancer in November of 2019 after filing her lawsuit six months earlier. The verdict included $50,000 in compensatory damages to Ms. Emerson\u2019s family and $200,000 in punitive damages against the company on claims … Continue reading \"Philadelphia Jury Returns $250,000 Verdict Against J&J in Latest Baby Powder-Ovarian Cancer Trial\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/philadelphia-jury-returns-250000-verdict-against-jj-in-latest-baby-powder-ovarian-cancer-trial\/","og_site_name":"Market Newsdesk","article_published_time":"2026-02-13T21:25:48+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260213785015r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/philadelphia-jury-returns-250000-verdict-against-jj-in-latest-baby-powder-ovarian-cancer-trial\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/philadelphia-jury-returns-250000-verdict-against-jj-in-latest-baby-powder-ovarian-cancer-trial\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Philadelphia Jury Returns $250,000 Verdict Against J&J in Latest Baby Powder-Ovarian Cancer Trial","datePublished":"2026-02-13T21:25:48+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/philadelphia-jury-returns-250000-verdict-against-jj-in-latest-baby-powder-ovarian-cancer-trial\/"},"wordCount":692,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/philadelphia-jury-returns-250000-verdict-against-jj-in-latest-baby-powder-ovarian-cancer-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260213785015r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/philadelphia-jury-returns-250000-verdict-against-jj-in-latest-baby-powder-ovarian-cancer-trial\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/philadelphia-jury-returns-250000-verdict-against-jj-in-latest-baby-powder-ovarian-cancer-trial\/","name":"Philadelphia Jury Returns $250,000 Verdict Against J&J in Latest Baby Powder-Ovarian Cancer Trial - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/philadelphia-jury-returns-250000-verdict-against-jj-in-latest-baby-powder-ovarian-cancer-trial\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/philadelphia-jury-returns-250000-verdict-against-jj-in-latest-baby-powder-ovarian-cancer-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260213785015r1&sid=flmnd&distro=nx&lang=en","datePublished":"2026-02-13T21:25:48+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/philadelphia-jury-returns-250000-verdict-against-jj-in-latest-baby-powder-ovarian-cancer-trial\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/philadelphia-jury-returns-250000-verdict-against-jj-in-latest-baby-powder-ovarian-cancer-trial\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/philadelphia-jury-returns-250000-verdict-against-jj-in-latest-baby-powder-ovarian-cancer-trial\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260213785015r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260213785015r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/philadelphia-jury-returns-250000-verdict-against-jj-in-latest-baby-powder-ovarian-cancer-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Philadelphia Jury Returns $250,000 Verdict Against J&J in Latest Baby Powder-Ovarian Cancer Trial"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/937041","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=937041"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/937041\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=937041"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=937041"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=937041"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}